SLC5A2 and type 2 diabetes mellitus: In the research by Pradhan et al., based on large cohorts of patients with type-2 diabetes in the United Kingdom, the authors confronted separately GLP-1RAs and sodium–glucose cotransporter 2 (SGLT-2) inhibitors with dipeptidyl peptidase 4 (DPP-4) inhibitors.